<DOC>
	<DOCNO>NCT00001530</DOCNO>
	<brief_summary>DDD pace improves symptoms relief LV outflow tract ( LVOT ) obstruction patient hypertrophic cardiomyopathy ( HCM ) . Notably , pace temporarily discontinue , beneficial effect pace evident sinus rhythm . The long term result novel therapy , however , uncertain . We propose ( 1 ) record hemodynamic change follow &gt; 4 year pace ; ( 2 ) determine whether DDD pace continue necessary patient substantial relief LVOT obstruction . Patients &gt; 50 % reduction LVOT pressure gradient randomize two pace modality : DDD 70 beat per minute AAI pace 70 beat per minute ( DDD switch ) , reevaluate six-month period .</brief_summary>
	<brief_title>Long-Term Results DDD Pacing Obstructive Hypertrophic Cardiomyopathy</brief_title>
	<detailed_description>DDD pace improves symptoms relief LV outflow tract ( LVOT ) obstruction patient hypertrophic cardiomyopathy ( HCM ) . Notably , pace temporarily discontinue , beneficial effect pace evident sinus rhythm . The long term result novel therapy , however , uncertain . We propose ( 1 ) record hemodynamic change follow &gt; 4 year pace ; ( 2 ) determine whether DDD pace continue necessary patient substantial relief LVOT obstruction . Patients &gt; 50 % reduction LVOT pressure gradient randomize two pace modality : DDD 70 beat per minute AAI pace 70 beat per minute ( DDD switch ) , reevaluate six-month period .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<criteria>Group 1 : HCM patient , age grater 20 year either gender receive DDD pacemaker NIH least 4 year ago , relief LVOT obstruction drugrefractory symptom . Group 2 : HCM patient select Group 1 followup cardiac catheterization demonstrate either ( 1 ) significant LVOT obstruction ( le 30mm HG rest le 50mm HG Isuprel ) ; ( 2 ) substantial reduction LVOT obstruction ( great 50 % reduction LVOT gradient ) . Patient develop heart block exclude group 2 . Females must negative pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1999</verification_date>
	<keyword>Cardiac Hypertrophy</keyword>
	<keyword>Drug-Refractory</keyword>
	<keyword>Hemodynamic Benefits</keyword>
	<keyword>Obstruction</keyword>
	<keyword>Pacemaker Therapy</keyword>
	<keyword>Hypertrophic Cardiomyopathy</keyword>
</DOC>